Prot #VRDN-001-301: A Randomized, Double-Masked, Placebo-Controlled Safety, Tolerability, and Efficacy Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants with Chronic Thyroid Eye Disease (TED)

Project: Research project

Project Details

StatusActive
Effective start/end date4/2/24 → 4/2/27

Funding

  • Parexel (Prot #VRDN-001-301 // Prot #VRDN-001-301)
  • miRagen Therapeutics, Inc. (Prot #VRDN-001-301 // Prot #VRDN-001-301)